David R. Patton

3.7k total citations
66 papers, 1.4k citations indexed

About

David R. Patton is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, David R. Patton has authored 66 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 22 papers in Molecular Biology and 20 papers in Oncology. Recurrent topics in David R. Patton's work include Lung Cancer Treatments and Mutations (14 papers), Cancer Genomics and Diagnostics (13 papers) and Colorectal Cancer Treatments and Studies (10 papers). David R. Patton is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Cancer Genomics and Diagnostics (13 papers) and Colorectal Cancer Treatments and Studies (10 papers). David R. Patton collaborates with scholars based in United States, Canada and Malaysia. David R. Patton's co-authors include Keith T. Flaherty, Barbara A. Conley, Carlos L. Arteaga, Lisa M. McShane, Edith P. Mitchell, Stanley R. Hamilton, Larry Rubinstein, Lyndsay N. Harris, Peter J. O’Dwyer and P. Mickey Williams and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

David R. Patton

57 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David R. Patton United States	18	473	348	326	294	288	66	1.4k
Cleofé Romagosa Spain	20	359 0.8×	146 0.4×	379 1.2×	339 1.2×	250 0.9×	52	1.6k
Sam Joseph Lubner United States	21	911 1.9×	157 0.5×	263 0.8×	464 1.6×	174 0.6×	73	1.6k
Jyoti Mayadev United States	27	610 1.3×	146 0.4×	134 0.4×	285 1.0×	235 0.8×	119	1.9k
Pieter J. Westenend Netherlands	27	925 2.0×	582 1.7×	277 0.8×	302 1.0×	904 3.1×	91	2.3k
Thierry Petit France	24	1.3k 2.8×	175 0.5×	542 1.7×	316 1.1×	718 2.5×	133	2.2k
Jan Starý Czechia	42	1.0k 2.2×	329 0.9×	1.5k 4.5×	203 0.7×	350 1.2×	255	5.0k
Fábio Távora United States	21	390 0.8×	80 0.2×	197 0.6×	658 2.2×	82 0.3×	68	1.4k
Peter Vuylsteke Belgium	19	1.1k 2.4×	115 0.3×	439 1.3×	411 1.4×	383 1.3×	101	1.7k
T. Le Chevalier France	23	1.6k 3.3×	395 1.1×	489 1.5×	984 3.3×	551 1.9×	60	2.6k
Stig Lenhoff Sweden	26	1.0k 2.2×	244 0.7×	877 2.7×	168 0.6×	107 0.4×	87	2.7k

Countries citing papers authored by David R. Patton

Since Specialization

Citations

This map shows the geographic impact of David R. Patton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Patton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Patton more than expected).

Fields of papers citing papers by David R. Patton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Patton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Patton. The network helps show where David R. Patton may publish in the future.

Co-authorship network of co-authors of David R. Patton

This figure shows the co-authorship network connecting the top 25 collaborators of David R. Patton. A scholar is included among the top collaborators of David R. Patton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David R. Patton. David R. Patton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McCourt, Carolyn K., Zihan Wei, Kevin Kalinsky, et al.. (2025). Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K. Clinical Cancer Research. 31(23). 4912–4919. 2 indexed citations

Ellison, Sara L., et al.. (2024). Galaxy evolution in the post-merger regime. II – Post-merger quenching peaks within 500 Myr of coalescence. SHILAP Revista de lepidopterología. 7. 8 indexed citations

O’Hara, Mark H., Opeyemi A. Jegede, Mark A. Dickson, et al.. (2024). Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C. Clinical Cancer Research. 31(1). 56–64. 1 indexed citations

Gettinger, Scott, Karen L. Reckamp, Jeffrey A. Moscow, et al.. (2024). Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A. JCO Precision Oncology. 8(8). e2300725–e2300725. 2 indexed citations

Macy, Margaret E., Rajen Mody, Joel M. Reid, et al.. (2024). Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). JCO Precision Oncology. 8(8). e2400418–e2400418. 2 indexed citations

Karlovich, Chris, Jennifer L. Silhavy, Biswajit Das, et al.. (2023). Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab).. Journal of Clinical Oncology. 41(16_suppl). 2560–2560.

Patton, David R., et al.. (2023). Repaired Tetralogy of Fallot Pressure Assessment: Insights from 4D-Flow Pressure Mapping. Fluids. 8(7). 196–196. 2 indexed citations

Das, Biswajit, Sorena Rahmanian, Jennifer L. Silhavy, et al.. (2023). Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T).. Journal of Clinical Oncology. 41(16_suppl). 3047–3047. 1 indexed citations

Subbiah, Vivek, Ragini R. Kudchadkar, Ryan J. Sullivan, et al.. (2022). Abstract CT160: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L. Cancer Research. 82(12_Supplement). CT160–CT160.

10.

Johnson, Douglas B., Fengmin Zhao, Marcus Smith Noel, et al.. (2020). Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clinical Cancer Research. 26(8). 1812–1819. 42 indexed citations

11.

Jhaveri, Komal, Vicky Makker, Shiuh‐Wen Luoh, et al.. (2019). Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Annals of Oncology. 30(11). 1821–1830. 90 indexed citations

12.

Tricoli, James V., Laura M. Yee, Lyndsay N. Harris, et al.. (2019). Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network.. Journal of Clinical Oncology. 37(15_suppl). 3016–3016. 3 indexed citations

13.

Banka, Puja, Joshua D. Robinson, Santosh C. Uppu, et al.. (2015). Cardiovascular magnetic resonance techniques and findings in children with myocarditis: a multicenter retrospective study. Journal of Cardiovascular Magnetic Resonance. 17(1). 96–96. 56 indexed citations

14.

Roy, Rupali, Andrew M. Evens, David R. Patton, et al.. (2012). Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. Leukemia & lymphoma. 54(3). 497–502. 14 indexed citations

15.

Friedrich, Matthias G., Éric Larose, David R. Patton, et al.. (2012). Canadian Society for Cardiovascular Magnetic Resonance (CanSCMR) Recommendations for Cardiovascular Magnetic Resonance Image Analysis and Reporting. Canadian Journal of Cardiology. 29(3). 260–265. 19 indexed citations

16.

Evens, Andrew M., William G. Spies, Irene Helenowski, et al.. (2009). The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial. Clinical Cancer Research. 15(20). 6462–6471. 15 indexed citations

17.

Evens, Andrew M., Leo I. Gordon, David R. Patton, et al.. (2008). Phase I Results of Combination Gemcitabine and Bortezomib (Velcade®) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL).. Blood. 112(11). 2005–2005. 6 indexed citations

18.

Sparkes, Rebecca, David R. Patton, & François P. Bernier. (2007). Cardiac features of a novel autosomal recessive dilated cardiomyopathic syndrome due to defective importation of mitochondrial protein. Cardiology in the Young. 17(2). 215–217. 35 indexed citations

19.

Evens, Andrew M., Jessica K. Altman, Bharat B. Mittal, et al.. (2007). Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Annals of Oncology. 18(4). 679–688. 16 indexed citations

20.

Roos, Noralou P., Randy Fransoo, Keumhee C. Carrière, et al.. (1999). Needs-Based Planning for Generalist Physicians. Medical Care. 37(SUPPLEMENT). JS206–JS228. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact